Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?

Key Takeaways Merck won FDA approval for a subcutaneous version of Keytruda, covering most solid tumor uses.The SC form takes as little as one minute to administer, versus at least 30 minutes for IV.Approval arrives as Keytruda faces 2028 patent expiry, with SC patents extending protection.Merck (MRK) announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab). This version, which will be marketed as Keytruda Qlex, is a ...